Antares Pharma, Inc.
- Jurisdiction
United States - LEI
5299004QMIHMZUUNYY44 - ISIN
US0366421065 (ATRS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. Read full profile
Stock price
Fundamentals
- Net revenue
€156.48M - Gross margin
61.5% - EBIT
€48.53M - EBIT margin
31.0% - Net income
€36.22M - Net margin
23.1%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: March 3, 2022